As of March 25, 2026, NVO (Novo Nordisk A/S Sponsored ADR) is in a falling knife state on the monthly chart, with a confidence level of 72%. Key support is at $36.0 and key resistance at $44.2. Monthly breakdown: price at ~$36.89 printed a large red close near lows, slicing back below the prior consolidation and sitting on/near the SMA200 (~$36.89) with heavy volume; RSI ~32 (weak momentum).
Bear continuation: a brief dead-cat bounce fails under the EMA200 area, followed by another leg down (Elliott: likely still in a Wave 3/extended C down) with price probing below the SMA200 before any durable base forms. Fib-wise, the $36 area is a major retracement zone of the 2022–2024 advance; a clean loss often opens the next pocket lower.
Bottoming attempt: price holds the SMA200 zone and forms a monthly higher low, then reclaims the EMA200 (~$44.25). That would fit an Elliott Wave 'Wave 4/base' or post-ABC stabilization, with a mean-reversion push toward the EMA100 (~$60.70) if momentum improves.
Monthly close below $36.00 (decisive break of SMA200 zone) would confirm continued FALLING_KNIFE risk.
Two consecutive monthly closes back above $44.25 (EMA200) would invalidate FALLING_KNIFE and shift toward a base/reversal thesis.
Scale near/under SMA200 support ($36) with adds into the next downside pocket; heavy add only if capitulation extends while watching for a monthly higher-low or reclaim of $44.25.
Trim into mean-reversion/major MA overhead supply (EMA100/EMA50/SMA50–100 zones), and fully exit near the prior cycle distribution area around the ~$120–$145 highs.
As of March 25, 2026, NVO (Novo Nordisk A/S Sponsored ADR) is in a falling knife state on the monthly chart with 72% confidence. Monthly breakdown: price at ~$36.89 printed a large red close near lows, slicing back below the prior consolidation and sitting on/near the SMA200 (~$36.89) with heavy volume; RSI ~32 (weak momentum).
On the monthly timeframe, NVO has key support at $36.0 and key resistance at $44.2. The most likely scenario (bearish) targets $32.0 and $28.0, with a revert level at $44.0.
NVO (Novo Nordisk A/S Sponsored ADR) is currently classified as falling knife on the monthly chart, with 72% confidence. Confirmation requires: Monthly close below $36.00 (decisive break of SMA200 zone) would confirm continued FALLING_KNIFE risk. This would be invalidated by: Two consecutive monthly closes back above $44.25 (EMA200) would invalidate FALLING_KNIFE and shift toward a base/reversal thesis.
The most likely scenario (bearish) targets $32.0 and $28.0, with a revert level at $44.0. The alternative scenario (bullish) targets $44.2 and $60.7.
Multi-layer AI agents analyse 200+ stocks across daily, weekly, and monthly timeframes — producing market state classifications, price scenarios with targets, and position entry/exit levels. Updated every trading day after market close. No paywall. No sign-up required.
Built by Foliotrail.
All content on this website — including charts, analysis, price targets, support/resistance levels, and position zones — is generated entirely by AI and provided for educational and informational purposes only.
This is not financial advice. NEXUSNOIR VENTURES SL (the operator of this website) is not a registered investment adviser or broker-dealer. You should not make investment decisions based solely on this information. Always do your own research and consult a qualified financial advisor.
By continuing, you acknowledge that you have read and agree to our full disclaimer & terms of use and privacy policy.
